Daniela Sorriento
Jessica Gambardella
Antonella Fiordelisi1
Guido Iaccarino
Maddalena Illario- 1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy
- 2Health Innovation Unit, Campania Region, Naples, Italy
Mitochondrial regulation of energy production, calcium homeostasis, and cell death are critical for cardiac function. Accordingly, the structural and functional abnormalities of these organelles (mitochondrial dysfunction) contribute to developing cardiovascular diseases and heart failure. Therefore the preservation of mitochondrial integrity is essential for cardiac cell survival. Mitochondrial function is regulated by several proteins, including GRK2 and β-arrestins which act in a GPCR independent manner to orchestrate intracellular signaling associated with key mitochondrial processes. It is now ascertained that GRK2 is able to recover mitochondrial function in response to insults. β-arrestins affect several intracellular signaling pathways within the cell which in turn are involved in the regulation of mitochondrial function, but a direct regulation of mitochondria needs further investigations. In this review, we discuss the recent acquisitions on the role of GRK2 and β-arrestins in the regulation of mitochondrial function.
Mitochondrial Functions in Damaged Heart
Known as “powerhouse” of the cell, mitochondria play essential roles in all human tissues, especially in those that are highly dependent on energy supply such as kidney, skeletal muscles, and myocardium. This latter, in particular, is the most metabolically active organ in the body. Its intense energy demand, needed to generate the contractile force, is supplied through the oxidative metabolism in mitochondria (Schaper et al., 1985; Barth et al., 1992; Hoppel et al., 2009). Therefore, it is not surprising that alterations of mitochondrial functions lead to the development of cardiac pathologies or susceptibility to injury. Indeed, mitochondrial dysfunction has been identified as the cause or a contributing factor in several heart diseases, thus several cardiac disorders, such heart failure, are currently defined “bioenergetic disease” (Murphy et al., 2016). However, beyond the regulation of energetic metabolism, mitochondria are now recognized to orchestrate multiple essential functions within the cell (Dorn, 2015). They sense smooth endoplasmic reticulum (ER) calcium release to modulate their metabolism and increase contractility (Chen et al., 2012; Dorn and Maack, 2013; Dorn, 2015). They are the main source of reactive oxygen species (ROS) to exert both physiological functions and pathological damage (Eisner et al., 2013). Moreover, mitochondria are the “gatekeepers” of programmed cell death (apoptosis and necrosis) (Wei et al., 2001; Whelan et al., 2012; Dorn, 2015). Also, these organelles are involved in the regulation of cardiomyocyte differentiation and embryonic cardiac development (Kasahara et al., 2013; Cho et al., 2014; Dorn, 2015). Thus, mitochondria exert both “energetic” and “non-energetic” functions (Figure 1) whose perturbations contribute to cardiac dysfunction (Rosenberg, 2004).
Figure 1. Energetic and non-energetic functions of mitochondria.
Energetic Metabolism
Several pieces of evidence support the idea that heart failure is a “bioenergetic diseases” associated with a loss of energetic supply (Neubauer et al., 1997; Ingwall and Weiss, 2004). Indeed, by means of nuclear magnetic resonance (NMR), it has been shown that a significant reduction of cardiac ATP and phosphocreatine (PCr) content occurs in patients with heart failure (Starling et al., 1998; Beer et al., 2002). Experimental models of heart failure show that impaired energetic metabolism leads to heart damage (Ciccarelli et al., 2011). In physiological conditions, the myocardium is characterized by an intensive ATP intake and turnover (Balaban et al., 1986) that is regulated by phosphocreatine levels, produced by mitochondrial creatine kinase (Ingwall et al., 1985; Soboll et al., 1999). In basal conditions, two forms of this enzyme (active and inactive) are in dynamic equilibrium and when this equilibrium is altered, results in impaired control of respiratory chain activity and reduction of mitochondrial ATP production (Ashrafian, 2002). Moreover, a significant reduction of individual electron transport complexes I and IV has been described in humans and animal model of heart failure (Lemieux et al., 2011; Rosca et al., 2011),associated with a reduction of functional super-complexes (Rosca et al., 2008). Defects in the mitochondrial respiratory chain have been observed both in early stage and end-stage of chronic heart failure (Lemieux et al., 2011). All these evidence confirm the involvement of impaired energetic metabolism in the development and progression of cardiac disease.
Mitochondrial ROS Production
Mitochondrial respiration through the electron transport chain (ETC) activity drives ATP synthesis and ROS production. In a healthy heart, the generation of superoxide radical is effectively neutralized by superoxide dismutase (Boveris et al., 1976). MnSOD silencing, the main mitochondrial antioxidant enzyme, is known to produce dilated cardiomyopathy leading to early postnatal death (Fukai and Ushio-Fukai, 2011). When mitochondrial respiration is compromised, decreased ATP production and increased oxidative stress occur (Lesnefsky et al., 2001). Elevated levels of ROS are able to induce oxidative modifications of specific mitochondrial proteins (Complex I and II, and Aconitase) that further stimulate ROS production in a vicious circle (Chen and Zweier, 2014). Moreover, a compromised antioxidant capacity also contributes to mitochondrial-mediated oxidative stress. The high levels of mitochondrial ROS induce alterations of main signaling pathways through oxidative modifications of important proteins such as cardiac ryanodine receptor (RyR2); indeed, the oxidation of this receptor alters its conformation and function contributing to the development of arrhythmias or heart failure (Oda et al., 2015).
Mitochondrial Dependent Apoptosis
It is ascertained that mitochondria, the primary sensor of metabolic stress, activate the programmed cell death. The mitochondria-dependent activation of apoptotic processes occurs in response to irreversible damage induced by intense or perpetuate metabolic stress (i.e., during acute or chronic ischemia) (Chistiakov et al., 2018). Such a condition increases mitochondrial permeability leading to cytochrome c release from mitochondria to the cytosol thus activating apoptosis (Karbowski et al., 2002). Besides this classical pathway, there are also other mechanisms by which mitochondria activates cell death in the failing heart (Dorn and Kirshenbaum, 2008; Dorn, 2010). During cardiac ischemia, a mitochondrial serine protease, known as high-temperature requirement A2 (HtrA2), is also released from mitochondria and promotes caspase activation and apoptosis (Dorn and Kirshenbaum, 2008; Piquereau et al., 2013). Several pieces of evidence suggest that abnormal cardiomyocyte apoptosis also occurs in both animal models and humans with arterial hypertension. Under this pathological stress, a functional cross-talk between death receptors pathways and mitochondrial-dependent apoptosis has been described, that is mediated by the Bcl2 family (Gonzalez et al., 2003). In addition, alterations of the mitochondrial apoptotic pathway have been described in both hypertrophic and dilative cardiomyopathy (Harvey and Leinwand, 2011). Overall the loss of cardiomyocytes due to apoptosis dysregulation is detrimental to cardiac function, and all recent studies support the key role of mitochondria in such phenomenon.
Mitochondrial Dynamics and Turnover
Mitochondrial fusion, fission, and trafficking, collectively called “mitochondrial dynamics”, are the regulators of Mitochondrial Quality Control, an essential process that preserves mitochondrial function and ensures cell survival (Ni et al., 2015; Shirihai et al., 2015; Sorriento et al., 2017). This process includes several mechanisms (Shirihai et al., 2015):
(a) fission/fusion, that allows segregation of damaged mitochondria;
(b) mitophagy, that removes the irreversibly damaged mitochondria;
(c) mitochondrial biogenesis, that ensures the generation of new intact mitochondria and new mtDNA molecules.
Perturbations of one or more of these mechanisms culminate in altered mitochondrial architecture and function. In failing heart, structural changes in mitochondria have been frequently observed, including giant mitochondria due to excessive mitochondrial fusion (Tandler et al., 2002). The balanced equilibrium between fusion and fission is switched toward fission during ischemia. Indeed, the up-regulation of dynamin-related protein 1 (Drp1), a key activator of mitochondrial fission, induces prominent mitochondrial fragmentation that in turn leads to loss of mitochondrial potential and apoptosis (Karbowski et al., 2002; Ong et al., 2010). Moreover, alterations in mitochondrial fragmentation or hyperplasia resulting from compromised fission/fusion balance have also been described in human and animal model of heart failure (Sabbah et al., 1992; Goh et al., 2016). The irreversibly damaged mitochondria are cleared in the cardiac cells by effective mitophagy, a tightly regulated process. In a healthy heart, PINK1 localizes on mitochondrial surface promoting parkin-dependent ubiquitination of MFN2 with the recruitment of several autophagy adaptors and formation of autophagosome around damaged mitochondria (Karbowski et al., 2002). Alterations in this pathway have been described in several cardiac diseases such as ischemic heart disease, cardiac hypertrophy, heart failure and dilated cardiomyopathy (Chistiakov et al., 2018). The mechanisms that lead to alterations in mitochondria clearance are not completely understood. Likely, an excessive autophagy occurs during acute cardiac injury leading also to the loss of functional organelles. On the contrary, mitophagy flux is reduced during the late stages of cardiac diseases thus promoting accumulation of damaged mitochondria, severe oxidative stress and cardiomyocytes apoptosis (Campos et al., 2016). Indeed, a reduction in autophagic activity is associated with poor prognosis of patients with heart disease (Campos et al., 2016). Beside the management of pre-existent mitochondria, also the de-novo synthesis of these organelles seems to be compromised in failing hearts. Replication of mtDNA is significantly impaired in heart failure resulting in depletion of mt-DNA-encoded proteins and in altered mitochondrial biogenesis (Karamanlidis et al., 2014). All these pieces of evidence suggest that mitochondrial turnover is a common compromised process in cardiac dysfunctions, pointing to another aspect of mitochondrial biology with a key role in cardiomyocyte function and survival.
Grks and β-Arrestins: the Non-Gpcr Signaling
G Protein-CoupledReceptor (GPCR) Kinase (GRKs) and β-arrestins are key regulators of GPCR signaling (Ferguson, 2001; Kohout and Lefkowitz, 2003; Santulli and Iaccarino, 2016; Sorriento et al., 2016). Indeed, GRKs are recruited to the plasma membrane when the receptor is activated by agonist binding. Here, GRKs phosphorylate GPCRs favoring the recruitment of β-arrestin which in turn promotes rapid receptors desensitization or their clathrin-mediated endocytosis and internalization (Ferguson et al., 1996; Goodman et al., 1996; Ferguson, 2001; Pierce et al., 2002; Lefkowitz and Shenoy, 2005). Several evidence endorse the proof of concept that GRKs and β-arrestins also regulate intracellular signaling independently from GPCR by affecting non-GPCR receptors or by direct interaction with target molecules (Kang et al., 2005; Ma and Pei, 2007; Penela et al., 2010; Evron et al., 2012). Among GRKs, GRK2 is emerging as a key node in signal transduction pathways, displaying a very complex “interactome” (Penela et al., 2010). β-arrestins also function as scaffold proteins that interact with several cytoplasmic molecules (DeFea et al., 2000; McDonald et al., 2000) or interact in the cytosol with regulators of transcription factors, such as IκBαand MDM2,to regulate transcription indirectly (Wang et al., 2003; Luan et al., 2005). Thus, these molecules are able to regulate several key processes within the cell in a GPCR-independent manner, affecting cell biology both in physiological and pathological conditions.
The functional cross-talk between mitochondria and other cellular compartments has been shown to regulate mitochondrial function (Hajnoczky et al., 2000; Galganska et al., 2010; Viola and Hool, 2010; Li et al., 2018). This interplay has a key physiological role, placing the mitochondria under the regulation of extracellular stimuli and thus ensuring the adaptation of mitochondrial activity to environmental needs. This functional cross-talk is regulated through the activity of several proteins, among whichGRK2 and β-arrestins are potential candidates. Indeed, these molecules are able to move among different compartments and interact with different partners thus interfering with the mitochondrial signaling transduction pathway. GRK2 and β-arrestins regulate mitochondrial function in cardiac cells through mechanisms which are independent of GPCR signaling. This issue was only recently investigated but several data have already been generated with important translational implications.
GRK2: A Dynamic and Multifunction Protein
GRKs are critical regulators of cardiac function both in physiological and pathological conditions. Among them, GRK2 and GRK5 are the most abundant G protein-coupled receptor kinases in the heart. In particular, GRK2 is essential for cardiac health. Indeed, the ablation of GRK2 gene in myocytes affects cardiac phenotypes in adulthood leading to a prevalent eccentric remodeling after chronic exposure to β adrenergic stimulation (Matkovich et al., 2006; Sorriento et al., 2015). Moreover, the total deletion of the kinase is lethal by preventing the correct development of the cardiovascular system in prenatal life (Raake et al., 2012). This developmental importance of GRK2 also concerns the endothelium. Indeed, the deletion of GRK2 in endothelial cells resulted in alteration of vascular phenotype and integrity, due to an increase of inflammation and oxidative stress (Ciccarelli et al., 2013; Rivas et al., 2013). Conversely, the deletion of GRK5 does not affect heart function but even ameliorates cardiac responses to insults (Hullmann et al., 2014). These data suggest that even though these kinases are both involved in the regulation of cardiac biology, GRK2 is the one fundamental for cardiac cell survival both in physiological and pathological conditions. It is clear that this effect could not be limited to the regulation of GPCR activity on plasma membrane where kinase effects seem, on the contrary, to trigger and sustain the development of heart failure (Lymperopoulos et al., 2012). That’s the reason why in the last decade research focused on the identification of other kinase activities within the cell which were independent of GPCR. A previous report from Mayor group clearly summarizes the novel identified GRK2 substrates and their functional roles in several conditions (cardiovascular diseases, inflammation, cancer) (Ribas et al., 2007; Penela et al., 2010). GRK2 has been shown to associate with PI3K, GIT, caveolin, MEK, AKT, α-actinin, clathrin, calmodulin, c-SRC, PKA, PKC, IkBα, and RKIP, regulating different signal transduction pathways within the cell (Ribas et al., 2007; Sorriento et al., 2015). Moreover, GRK2 can also interact with non–GPCR receptors, such as Ins-R, PDGF-R, and EGF-R (Hupfeld and Olefsky, 2007; Cipolletta et al., 2009).
Based on these findings, the idea that GRK2 is a dynamic molecule, that moves within the cell depending on cell requirements, started to take ground (Sorriento et al., 2014; Sorriento et al., 2016) suggesting that the regulation of GRK2 trafficking within the cell could be a potential strategy to regulate the adaptative effects of the kinase on cell functions (Sorriento et al., 2014).
β-Arrestins and the Signalosomes
Besides their cardioprotective role through means of GPCR desensitization, common acquisitions suggest that β-arrestins also function as GPCR signal transducers (Luttrell and Lefkowitz, 2002). They directly initiate signaling through the formation of multiprotein signaling complexes, known as a “signalosomes,” in which they act as scaffolds, adaptors, and signal transduction proteins (Lefkowitz et al., 2006). They can form complexes with several signaling proteins, including Src family tyrosine kinases and components of the ERK1/2 and JNK3 MAP kinase cascades (DeWire et al., 2007; Kang et al., 2014). Moreover, β-arrestins can also regulate gene transcription in the nucleus. Indeed, they are able to interact with IkBα and sequester the complex IkBα-NFkB in the cytosol, thus inhibiting NFkB transcription activity (Witherow et al., 2004). More than 300 proteins have been identified that interact with β-arrestins with multiple implications in most key processes within the cell (Xiao et al., 2007). These proteins are mainly localized in the cytosol but they are also distributed in other compartments including mitochondria.
Grk2 Dependent Regulation of Mitochondrial Function
Energetic Metabolism and Mitochondrial Dynamics
Among the novel functions of GRK2, in the last decade, the potential role of the kinase in the regulation of the metabolic state of the cell emerged (Cipolletta et al., 2009; Sorriento et al., 2014). The evidence comes from the demonstration that GRK2 accumulation leads to the shut-off of insulin signaling and inhibits glucose extraction (Usui et al., 2004; Cipolletta et al., 2009; Ciccarelli et al., 2011). In the cardiovascular setting, given the key role of mitochondria to supply the energy need of the heart and the importance of GRK2 for cardiac biology, research also focused on the identification of a potential role of GRK2 in the regulation of energy metabolism leading to the discovery of GRK2as key mediator of production and expenditure of energy within the cell (Fusco et al., 2012; Chen et al., 2013). The first evidence of GRK2 localization at mitochondria comes from the study of Obrenovich’s group in a rat model of Alzheimer disease (Obrenovich et al., 2006). In the early pathogenesis of Alzheimer Disease and in ischemia-reperfusion brain injury models, GRK2 accumulates in damaged mitochondria, suggesting a role for the kinase in this organelle. However, Fusco and colleagues were the first who effectively identified the kinase role in mitochondria (Fusco et al., 2012). Indeed, they showed that the overexpression of this kinase increased mitochondrial mass, ATP production and mitochondrial biogenesis (Fusco et al., 2012). Ischemia causes acute accumulation of GRK2 in mitochondria both in vitro and in vivo, and reperfusion reverted such effect. The overexpression of the kinase protects ATP production even after hypoxia/reperfusion damage (Fusco et al., 2012). This suggests a potential role of the kinase in energy production, which is particularly relevant for tissues that need a great amount of energy to work well, such as the heart. Successively, other reports confirmed that GRK2 localizes into mitochondria. Indeed, Chen showed that both in hearts in vivo and in cultured myocytes, GRK2 localizes into mitochondria after an ischemia-reperfusion insult. The authors also propose a potential mechanism by which the kinase is able to traffic to mitochondria (Chen et al., 2013). In particular, they demonstrate that phosphorylation at residue Ser670 within the carboxyl-terminus of GRK2 by extracellular signal-regulated kinase (ERK) allows GRK2 to bind the heat shock protein 90 (HSP90), which chaperones the kinase to mitochondria (Chen et al., 2013). Accordingly, the same Authors also show that a mutant form of GRK2, that cannot bind HSP90, does not localize to mitochondria (Sato et al., 2018). Mitochondrial localization of the kinase is not limited to cardiac cells. Indeed, we demonstrated that GRK2 localizes into mitochondria of macrophagic cells in a time-dependent manner and an early translocation supports the cell to better respond to LPS dependent mitochondrial dysfunction (Sorriento et al., 2013). In these cells, the overexpression of the carboxy-terminal domain of GRK2 (βARK-ct), known to displace GRK2 from plasma membranes, induces earlier localization of GRK2 to mitochondria in response to LPS leading to increased mt-DNA transcription and reduced ROS production and cytokine expression (Sorriento et al., 2013). These data confirm that the mitochondrial localization of GRK2 ameliorates mitochondrial function, as shown in other models (Fusco et al., 2012). Accordingly, Franco recently showed that the overexpression of GRK2 protects mitochondria from the damage induced by ionizing radiation. Indeed, GRK2 favors the rescue of mitochondrial mass, morphology, and respiration (Franco et al., 2018). On the opposite, the kinase deletion accelerates degenerative processes induced by the exposure to ionizing radiation. This evidence clearly supports the idea that GRK2 is beneficial for mitochondrial function and is effective to protect mitochondria from insults. The mechanism involves a novel “interactome” of GRK2 which includes HSP90, as also previously demonstrated (Chen et al., 2013), and molecules involved in the regulation of mitochondrial dynamics, mitofusins (MFN-1 and MFN-2) (Franco et al., 2018). GRK2 dynamically binds MFN-1/2 by means of HSP90 and phosphorylates these molecules affecting mitochondrial fusion (Franco et al., 2018). MFN-1 and 2 are key regulators of mitochondrial fusion and fission processes that are critical for cardiac health (Santel, 2006). Recently, it has been demonstrated that these molecules can adopt either a fusion-constrained or a fusion-permissive molecular conformation that allows them to regulate mitochondrial dynamics (Franco et al., 2016). The imbalance between fission and fusion causes mitochondrial dysfunction. The finding that GRK2 is able to phosphorylate and activate these molecules suggest its involvement in mitochondrial dynamics and biology. This is the first finding regarding a phosphorylation-dependent regulation of the activity of the mitofusins. Likely, GRK2 by phosphorylating mitofusins can orchestrate mitochondrial dynamics. However, further data are needed to support this hypothesis.
Apoptosis
Even though all in vitro findings strongly support a protective effect of GRK2 in damaged mitochondria, other reports, on the contrary, suggest a pro-death role of the kinase in this organelle. Indeed, in cardiac myocytes, the inhibition of GRK2 increased ATP production whereas the overexpression of the kinase increased oxidative stress and negatively regulated FA oxidation (Sato et al., 2015). Moreover, mitochondrial GRK2 is reported to promote cell death in ischemic myocytes and its inhibition by means of βARKct is reported to be cardioprotective.(Chen et al., 2013; Woodall et al., 2014). Conversely, the same authors previously published that this pro-apoptotic effect of GRK2 was only due to its effects on plasma membrane through the regulation of AKT signaling, also showing that the treatment with βARK-ct inhibited such phenomenon (Brinks et al., 2010). Thus, it is not clear yet whether the effects of βARK-ct could depend on GRK2 reduction in mitochondria or in the plasma membrane. Further studies are needed to better clarify this issue.
Also, the same Authors recently show that a mutant form of GRK2, that cannot bind HSP90, inhibits kinase localization in mitochondria and confers protection in response to ischemia-reperfusion (Sato et al., 2018).
In this context, the disruption of GRK2 binding with HSP90 has been shown to decrease the expression of endogenous GRK2 in a dose- and time-dependent manner (Luo and Benovic, 2003) and this could justify the cardioprotective role of βARKct and of GRK2 mutant. Given this evidence, it was expected that both βARKct and the expression of the mutant form of GRK2 would cause the total reduction of the kinase within the cell. Actually, total levels of GRK2 were not modified in both Chen’s and Sato’s studies which are therefore in contrast with literature. Given these discrepancies, the exact role of mitochondrial GRK2 in apoptotic processes still remains to be clarified.
GRK2 in Mitochondria: Detrimental or Cardioprotective?
Actually, contrasting evidence exists on the role of GRK2 in mitochondria. To reconcile these opposing findings, several considerations are to be taken into account.
(a) Membrane displacement of GRK2 from the plasma membrane by means of βARKct overexpression does not mean lack of kinase activity. βARKct reduces GRK2 levels on the plasma membrane but also induces its localization in other cellular compartments, such as mitochondria (Sorriento et al., 2013). Giving this notion, the cardioprotective effect of βARKct in ischemic myocytes is in agreement with kinase accumulation in mitochondria.
(b) The overexpression is a complex maneuver that drastically upsets cell biology. Indeed, GRK2 overexpression increased kinase levels in all cellular compartments, including plasma membranes, whereGRK2induces apoptotic events by affecting GPCR signaling. Indeed, GRK2 induces oxidative stress and apoptosis in cardiac myocytes in the same manner of beta-adrenergic receptor stimulation, and kinase inhibition prevents such events (Theccanat et al., 2016). Thus, GRK2 dependent induction of apoptosis depends on its levels of expression on membranes being limited to its effects on GPCR signaling independently from mitochondria.
(c) Moreover, it should be considered that in response to insults the cell activates protective mechanisms to avoid irreversible damage. Mitochondrial fission, for instance, is activated to better respond to stress conditions by eliminating damaged mitochondria and restoring the normal cell activity. The apoptosis is a programmed cell death that is induced when cell damage is irreversible. Therefore, GRK2 dependent cell death could not be strictly dependent on a deleterious action of the kinase but would rather be the result of an advanced and irreversible mitochondrial damage that GRK2 is not able to stop.
(d) Timing is also a critical point to take into account. Indeed, the protective role of GRK2 has been shown in response to acute insults but the chronic responses in animal models could be different and negatively affect mitochondrial biology due to continuous activation of intracellular signaling.
Thus, altogether these findings support the proof of concept that GRK2 is a dynamic and multifunction protein whose actions in mitochondria likely aims to protect the cell from irreversible damage due to external insults (Figure 2). This activity is especially significant in those conditions, such as heart failure, characterized by remarkable mitochondrial dysfunction. Thus, the possibility to specifically deliver the kinase to mitochondria (i.e., through means of plasma membrane displacement such as βARK-ct) appears a promising strategy to recover mitochondrial function in damaged cardiac cells.
Figure 2. GRK2 activities in mitochondria.
β-Arrestins and Mitochondrial Activity
Among the numerous actions of β-arrestins within the cell, growing evidence suggests their involvement in the regulation of mitochondrial function in the heart. In particular, it has been shown that such proteins interfere with key mitochondrial processes such as cell death, ROS production, and respiration. The involvement of β-arrestins in the regulation of apoptotic processes is very controversial. Indeed, it has been suggested that these proteins can both promote and inhibit cell death probably due to different stimuli and cell type. In Mouse Embryonic Fibroblasts (MEFs), in response to apoptotic stimuli, β-arrestins are cleaved by multiple caspases at Asp380 generating a small fragment of 380 amino acids (Kook et al., 2014). This latter translocates to mitochondria and cooperates with tBID to induce the release of cytochrome C and consequently cell death (Youle and Strasser, 2008; Galluzzi et al., 2012). Conversely, in response to IGF-1 stimulation,β-arrestins mediate the activation of PI3K with subsequent activation of AKT (Gu et al., 2015). The PI3-kinase/AKT signaling pathway blocks caspase activity and consequently apoptosis (Kennedy et al., 1997). Also, in response to oxidative stressβ-arrestins exert an anti-apoptotic effect. Indeed, in HEK-293 cells stimulated with H2O2 β-arrestins bind the C-terminal domain of the Apoptosis Signal-regulating Kinase 1 (ASK1) inducing its ubiquitination and degradation by the proteasome (Zhang et al., 2009). Giving these opposing findings, further data are needed to better clarify the involvement of β-arrestins in apoptotic processes.
It is known that mitochondria represent the major intracellular source of ROS. β-arrestins are able to regulate mitochondrial ROS production (Philip et al., 2015). In cultured human cardiac fibroblasts isolated from failing hearts, there is an upregulation of β-arrestins that is associated with the activation of ERK and subsequent upregulation of Nox4, an NADPH oxidase able to catalyze the production of a superoxide free radical. This increase in oxidative stress promotes collagen synthesis and leads to myocardial fibrosis (Tsutsui et al., 2011). The overexpression of β-arrestins by means of adenoviral-mediated gene transfer increases mitochondrial superoxide production while the knockdown decreased ROS production and Nox4 expression in failing cardiac fibroblasts (Philip et al., 2015). Thus, targeted inhibition of β-arrestins in cardiac fibroblasts could be an effective strategy to decrease oxidative stress and fibrosis in cardiac tissue. Both β-arrestin 1 and β-arrestin 2 are both expressed in cardiac myocytes but it has been shown that only β-arrestin 1 is involved in βAR induced ROS production (J. Zhang et al., 2017). Indeed, the knockdown of β-arrestin1 inhibited βAR dependent mitochondrial ROS production while the knockdown of β-arrestin 2 exerted no effects. The mitochondrial production of ROS in response to βAR stimulation is activated by two different pathways at different times. Indeed, this study shows that the cAMP/PKA pathway is responsible for faster mitochondrial ROS production, whereas β-arrestin1 signaling is responsible for the slower one (Zhang et al., 2017).
Among β-arrestins interactome, many proteins participate to mitochondrial respiration (Gu et al., 2015), including metabolic enzymes involved in the glycolysis pathway (PK3, GAPDH, and enolase) and oxidative phosphorylation (ATP synthases and SDH2) (Xiao et al., 2007). The functional implications of such interactions are still unknown but likely β-arrestins interactions with these enzymes could be needed to promote energy production.
Compared with GRK2, the involvement of β-arrestins in the regulation of mitochondrial function needs more clarifications. However, the available findings suggest thatβ-arrestins interfere with several intracellular signaling pathways which are involved in the regulation of key mitochondrial processes (Figure 3) and could be a promising target for the regulation of mitochondrial function.
Figure 3. Non-GPCR activities of β-arrestins.
Conclusion
Several reports support the proof of concept that GRK2 and β-arrestins are able to regulate intracellular signaling in a GPCR independent manner. These activities affect several compartments within the cell, including mitochondria. The involvement of GRK2 in the regulation of mitochondrial function has been recently identified showing its ability to regulate ATP content, ROS production, mitochondrial dynamics, and apoptosis. However, the exact role of the kinase (detrimental or protective) still remains to be elucidated given the opposing results from reports on this issue. Overall, we tried to reconcile these opposing findings pointing to a protective role of GRK2 in mitochondria through its binding to HSP90. Such an effect has important implications in the onset of cardiovascular disease, which are characterized by an impaired mitochondrial function. In this context, β-arrestins are novel identified targets whose activities in mitochondria are not completely clear yet. Few studies are available on β-arrestins dependent regulation of mitochondrial functions thus further investigations are needed. However, the available ones strongly suggest the involvement of β-arrestins in the regulation of mitochondrial ROS production and mitochondrial respiration. The better understanding of the role of these proteins in mitochondria could have important implications providing the basis for new therapeutic approaches to treat mitochondrial dysfunction in cardiovascular diseases.
Author Contributions
DS and GI conceived the study. DS, JG, AF, GI, and MI wrote and critically reviewed the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Balaban, R. S., Kantor, H. L., Katz, L. A., and Briggs, R. W. (1986). Relation between work and phosphate metabolite in the in vivo paced mammalian heart. Science 232, 1121–1123.
Barth, E., Stammler, G., Speiser, B., and Schaper, J. (1992). Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J. Mol. Cell. Cardiol. 24, 669–681.
Beer, M., Seyfarth, T., Sandstede, J., Landschutz, W., Lipke, C., Kostler, H., et al. (2002). Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 40, 1267–1274.
Boveris, A., Cadenas, E., and Stoppani, A. O. (1976). Role of ubiquinone in the mitochondrial generation of hydrogen peroxide. Biochem. J. 156, 435–444.
Brinks, H., Boucher, M., Gao, E., Chuprun, J. K., Pesant, S., Raake, P. W., et al. (2010). Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ. Res. 107, 1140–1149. doi: 10.1161/CIRCRESAHA.110.221010
Campos, J. C., Bozi, L. H., Bechara, L. R., Lima, V. M., and Ferreira, J. C. (2016). Mitochondrial quality control in cardiac diseases. Front. Physiol. 7:479. doi: 10.3389/fphys.2016.00479
Chen, M., Sato, P. Y., Chuprun, J. K., Peroutka, R. J., Otis, N. J., Ibetti, J., et al. (2013). Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting. Circ. Res. 112, 1121–1134. doi: 10.1161/CIRCRESAHA.112.300754
Chen, Y., Csordas, G., Jowdy, C., Schneider, T. G., Csordas, N., Wang, W., et al. (2012). Mitofusin 2-containing mitochondrial-reticular microdomains direct rapid cardiomyocyte bioenergetic responses via interorganelle Ca2+ crosstalk. Circ. Res. 111, 863–875. doi: 10.1161/CIRCRESAHA.112.266585
Chen, Y. R., and Zweier, J. L. (2014). Cardiac mitochondria and reactive oxygen species generation. Circ. Res. 114, 524–537. doi: 10.1161/CIRCRESAHA.114.300559
Chistiakov, D. A., Shkurat, T. P., Melnichenko, A. A., Grechko, A. V., and Orekhov, A. N. (2018). The role of mitochondrial dysfunction in cardiovascular disease: a brief review. Ann. Med. 50, 121–127. doi: 10.1080/07853890.2017.1417631
Cho, S. W., Park, J. S., Heo, H. J., Park, S. W., Song, S., Kim, I., et al. (2014). Dual modulation of the mitochondrial permeability transition pore and redox signaling synergistically promotes cardiomyocyte differentiation from pluripotent stem cells. J. Am. Heart Assoc. 3:e000693. doi: 10.1161/JAHA.113.000693
Ciccarelli, M., Chuprun, J. K., Rengo, G., Gao, E., Wei, Z., Peroutka, R. J., et al. (2011). G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 123, 1953–1962. doi: 10.1161/CIRCULATIONAHA.110.988642
Ciccarelli, M., Sorriento, D., Franco, A., Fusco, A., Del Giudice, C., Annunziata, R., et al. (2013). Endothelial G protein-coupled receptor kinase 2 regulates vascular homeostasis through the control of free radical oxygen species. Arterioscler. Thromb. Vasc. Biol. 33, 2415–2424. doi: 10.1161/ATVBAHA.113.302262
Cipolletta, E., Campanile, A., Santulli, G., Sanzari, E., Leosco, D., Campiglia, P., et al. (2009). The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance. Cardiovasc. Res. 84, 407–415. doi: 10.1093/cvr/cvp252
DeFea, K. A., Zalevsky, J., Thoma, M. S., Dery, O., Mullins, R. D., and Bunnett, N. W. (2000). beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J. Cell Biol. 148, 1267–1281.
DeWire, S. M., Ahn, S., Lefkowitz, R. J., and Shenoy, S. K. (2007). Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69, 483–510. doi: 10.1146/annurev.ph.69.013107.100021
Dorn, G. W. II (2010). Mitochondrial pruning by Nix and BNip3: an essential function for cardiac-expressed death factors. J. Cardiovasc. Transl. Res. 3, 374–383. doi: 10.1007/s12265-010-9174-x
Dorn, G. W. II (2015). Mitochondrial dynamism and heart disease: changing shape and shaping change. EMBO Mol. Med. 7, 865–877. doi: 10.15252/emmm.201404575
Dorn, G. W. II, and Kirshenbaum, L. A. (2008). Cardiac reanimation: targeting cardiomyocyte death by BNIP3 and NIX/BNIP3L. Oncogene 27(Suppl. 1), S158–S167. doi: 10.1038/onc.2009.53
Dorn, G. W. II, and Maack, C. (2013). SR and mitochondria: calcium cross-talk between kissing cousins. J. Mol. Cell. Cardiol. 55, 42–49. doi: 10.1016/j.yjmcc.2012.07.015
Eisner, V., Csordas, G., and Hajnoczky, G. (2013). Interactions between sarco-endoplasmic reticulum and mitochondria in cardiac and skeletal muscle - pivotal roles in Ca2+ and reactive oxygen species signaling. J. Cell Sci. 126(Pt 14), 2965–2978. doi: 10.1242/jcs.093609
Evron, T., Daigle, T. L., and Caron, M. G. (2012). GRK2: multiple roles beyond G protein-coupled receptor desensitization. Trends Pharmacol. Sci. 33, 154–164. doi: 10.1016/j.tips.2011.12.003
Ferguson, S. S. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1–24.
Ferguson, S. S., Downey, W. E. III, Colapietro, A. M., Barak, L. S., Menard, L., and Caron, M. G. (1996). Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271, 363–366.
Franco, A., Kitsis, R. N., Fleischer, J. A., Gavathiotis, E., Kornfeld, O. S., Gong, G., et al. (2016). Correcting mitochondrial fusion by manipulating mitofusin conformations. Nature 540, 74–79. doi: 10.1038/nature20156
Franco, A., Sorriento, D., Gambardella, J., Pacelli, R., Prevete, N., Procaccini, C., et al. (2018). GRK2 moderates the acute mitochondrial damage to ionizing radiation exposure by promoting mitochondrial fission/fusion. Cell Death Discov. 4:25. doi: 10.1038/s41420-018-0028-7
Fukai, T., and Ushio-Fukai, M. (2011). Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal. 15, 1583–1606. doi: 10.1089/ars.2011.3999
Fusco, A., Santulli, G., Sorriento, D., Cipolletta, E., Garbi, C., Dorn, G. W., et al. (2012). Mitochondrial localization unveils a novel role for GRK2 in organelle biogenesis. Cell. Signal. 24, 468–475. doi: 10.1016/j.cellsig.2011.09.026
Galganska, H., Karachitos, A., Wojtkowska, M., Stobienia, O., Budzinska, M., and Kmita, H. (2010). Communication between mitochondria and nucleus: putative role for VDAC in reduction/oxidation mechanism. Biochim. Biophys. Acta 1797, 1276–1280. doi: 10.1016/j.bbabio.2010.02.004
Galluzzi, L., Kepp, O., and Kroemer, G. (2012). Mitochondria: master regulators of danger signalling. Nat. Rev. Mol. Cell. Biol. 13, 780–788. doi: 10.1038/nrm3479
Goh, K. Y., Qu, J., Hong, H., Liu, T., Dell’Italia, L. J., Wu, Y., et al. (2016). Impaired mitochondrial network excitability in failing guinea-pig cardiomyocytes. Cardiovasc. Res. 109, 79–89. doi: 10.1093/cvr/cvv230
Gonzalez, A., Fortuno, M. A., Querejeta, R., Ravassa, S., Lopez, B., Lopez, N., et al. (2003). Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc. Res. 59, 549–562.
Goodman, O. B. Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., et al. (1996). Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383, 447–450. doi: 10.1038/383447a0
Gu, Y. J., Sun, W. Y., Zhang, S., Wu, J. J., and Wei, W. (2015). The emerging roles of beta-arrestins in fibrotic diseases. Acta Pharmacol. Sin. 36, 1277–1287. doi: 10.1038/aps.2015.74
Hajnoczky, G., Csordas, G., Madesh, M., and Pacher, P. (2000). The machinery of local Ca2+ signalling between sarco-endoplasmic reticulum and mitochondria. J. Physiol. 529(Pt 1), 69–81.
Harvey, P. A., and Leinwand, L. A. (2011). The cell biology of disease: cellular mechanisms of cardiomyopathy. J. Cell Biol. 194, 355–365. doi: 10.1083/jcb.201101100
Hoppel, C. L., Tandler, B., Fujioka, H., and Riva, A. (2009). Dynamic organization of mitochondria in human heart and in myocardial disease. Int. J. Biochem. Cell Biol. 41, 1949–1956. doi: 10.1016/j.biocel.2009.05.004
Hullmann, J. E., Grisanti, L. A., Makarewich, C. A., Gao, E., Gold, J. I., Chuprun, J. K., et al. (2014). GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ. Res. 115, 976–985. doi: 10.1161/CIRCRESAHA.116.304475
Hupfeld, C. J., and Olefsky, J. M. (2007). Regulation of receptor tyrosine kinase signaling by GRKs and beta-arrestins. Annu. Rev. Physiol. 69, 561–577. doi: 10.1146/annurev.physiol.69.022405.154626
Ingwall, J. S., Kramer, M. F., Fifer, M. A., Lorell, B. H., Shemin, R., Grossman, W., et al. (1985). The creatine kinase system in normal and diseased human myocardium. N. Engl. J. Med. 313, 1050–1054. doi: 10.1056/NEJM198510243131704
Ingwall, J. S., and Weiss, R. G. (2004). Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ. Res. 95, 135–145. doi: 10.1161/01.RES.0000137170.41939.d9
Kang, D. S., Tian, X., and Benovic, J. L. (2014). Role of beta-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. Curr. Opin. Cell Biol. 27, 63–71. doi: 10.1016/j.ceb.2013.11.005
Kang, J., Shi, Y., Xiang, B., Qu, B., Su, W., Zhu, M., et al. (2005). A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 123, 833–847. doi: 10.1016/j.cell.2005.09.011
Karamanlidis, G., Garcia-Menendez, L., Kolwicz, S. C. Jr., Lee, C. F., and Tian, R. (2014). Promoting PGC-1alpha-driven mitochondrial biogenesis is detrimental in pressure-overloaded mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 307, H1307–H1316. doi: 10.1152/ajpheart.00280.2014
Karbowski, M., Lee, Y. J., Gaume, B., Jeong, S. Y., Frank, S., Nechushtan, A., et al. (2002). Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J. Cell Biol. 159, 931–938. doi: 10.1083/jcb.200209124
Kasahara, A., Cipolat, S., Chen, Y., Dorn, G. W. II, and Scorrano, L. (2013). Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. Science 342, 734–737. doi: 10.1126/science.1241359
Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N., et al. (1997). The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11, 701–713.
Kohout, T. A., and Lefkowitz, R. J. (2003). Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol. 63, 9–18.
Kook, S., Zhan, X., Cleghorn, W. M., Benovic, J. L., Gurevich, V. V., and Gurevich, E. V. (2014). Caspase-cleaved arrestin-2 and BID cooperatively facilitate cytochrome C release and cell death. Cell Death Differ. 21, 172–184. doi: 10.1038/cdd.2013.143
Lefkowitz, R. J., Rajagopal, K., and Whalen, E. J. (2006). New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol. Cell 24, 643–652. doi: 10.1016/j.molcel.2006.11.007
Lefkowitz, R. J., and Shenoy, S. K. (2005). Transduction of receptor signals by beta-arrestins. Science 308, 512–517. doi: 10.1126/science.1109237
Lemieux, H., Semsroth, S., Antretter, H., Hofer, D., and Gnaiger, E. (2011). Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. Int. J. Biochem. Cell Biol. 43, 1729–1738. doi: 10.1016/j.biocel.2011.08.008
Lesnefsky, E. J., Moghaddas, S., Tandler, B., Kerner, J., and Hoppel, C. L. (2001). Mitochondrial dysfunction in cardiac disease: ischemia–reperfusion, aging, and heart failure. J. Mol. Cell. Cardiol. 33, 1065–1089. doi: 10.1006/jmcc.2001.1378
Li, Q., Lei, F., Tang, Y., Pan, J. S., Tong, Q., Sun, Y., et al. (2018). Megalin mediates plasma membrane to mitochondria cross-talk and regulates mitochondrial metabolism. Cell. Mol. Life Sci. 75, 4021–4040. doi: 10.1007/s00018-018-2847-3
Luan, B., Zhang, Z., Wu, Y., Kang, J., and Pei, G. (2005). Beta-arrestin2 functions as a phosphorylation-regulated suppressor of UV-induced NF-kappaB activation. EMBO J. 24, 4237–4246. doi: 10.1038/sj.emboj.7600882
Luo, J., and Benovic, J. L. (2003). G protein-coupled receptor kinase interaction with Hsp90 mediates kinase maturation. J. Biol. Chem. 278, 50908–50914. doi: 10.1074/jbc.M307637200
Luttrell, L. M., and Lefkowitz, R. J. (2002). The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115(Pt 3), 455–465.
Lymperopoulos, A., Rengo, G., and Koch, W. J. (2012). GRK2 inhibition in heart failure: something old, something new. Curr. Pharm. Des. 18, 186–191.
Ma, L., and Pei, G. (2007). Beta-arrestin signaling and regulation of transcription. J. Cell Sci. 120(Pt 2), 213–218. doi: 10.1242/jcs.03338
Matkovich, S. J., Diwan, A., Klanke, J. L., Hammer, D. J., Marreez, Y., Odley, A. M., et al. (2006). Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ. Res. 99, 996–1003. doi: 10.1161/01.RES.0000247932.71270.2c
McDonald, P. H., Chow, C. W., Miller, W. E., Laporte, S. A., Field, M. E., Lin, F. T., et al. (2000). Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290, 1574–1577.
Murphy, E., Ardehali, H., Balaban, R. S., DiLisa, F., Dorn, G. W. II, Kitsis, R. N., et al. (2016). Mitochondrial function, biology, and role in disease: a scientific statement from the American heart association. Circ. Res. 118, 1960–1991. doi: 10.1161/RES.0000000000000104
Neubauer, S., Horn, M., Cramer, M., Harre, K., Newell, J. B., Peters, W., et al. (1997). Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96, 2190–2196.
Ni, H. M., Williams, J. A., and Ding, W. X. (2015). Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 4, 6–13. doi: 10.1016/j.redox.2014.11.006
Obrenovich, M. E., Smith, M. A., Siedlak, S. L., Chen, S. G., de la Torre, J. C., Perry, G., et al. (2006). Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox Res. 10, 43–56.
Oda, T., Yang, Y., Uchinoumi, H., Thomas, D. D., Chen-Izu, Y., Kato, T., et al. (2015). Oxidation of ryanodine receptor (RyR) and calmodulin enhance Ca release and pathologically alter, RyR structure and calmodulin affinity. J. Mol. Cell. Cardiol. 85, 240–248. doi: 10.1016/j.yjmcc.2015.06.009
Ong, S. B., Subrayan, S., Lim, S. Y., Yellon, D. M., Davidson, S. M., and Hausenloy, D. J. (2010). Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 121, 2012–2022. doi: 10.1161/CIRCULATIONAHA.109.906610
Penela, P., Murga, C., Ribas, C., Lafarga, V., and Mayor, F. Jr. (2010). The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br. J. Pharmacol. 160, 821–832. doi: 10.1111/j.1476-5381.2010.00727.x
Philip, J. L., Razzaque, M. A., Han, M., Li, J., Theccanat, T., Xu, X., et al. (2015). Regulation of mitochondrial oxidative stress by beta-arrestins in cultured human cardiac fibroblasts. Dis. Model. Mech. 8, 1579–1589. doi: 10.1242/dmm.019968
Pierce, K. L., Premont, R. T., and Lefkowitz, R. J. (2002). Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3, 639–650. doi: 10.1038/nrm908
Piquereau, J., Caffin, F., Novotova, M., Lemaire, C., Veksler, V., Garnier, A., et al. (2013). Mitochondrial dynamics in the adult cardiomyocytes: which roles for a highly specialized cell? Front. Physiol. 4:102. doi: 10.3389/fphys.2013.00102
Raake, P. W., Zhang, X., Vinge, L. E., Brinks, H., Gao, E., Jaleel, N., et al. (2012). Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation 125, 2108–2118. doi: 10.1161/CIRCULATIONAHA.111.044255
Ribas, C., Penela, P., Murga, C., Salcedo, A., Garcia-Hoz, C., Jurado-Pueyo, M., et al. (2007). The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim. Biophys. Acta 1768, 913–922. doi: 10.1016/j.bbamem.2006.09.019
Rivas, V., Carmona, R., Munoz-Chapuli, R., Mendiola, M., Nogues, L., Reglero, C., et al. (2013). Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. J. Clin. Invest. 123, 4714–4730. doi: 10.1172/JCI67333
Rosca, M., Minkler, P., and Hoppel, C. L. (2011). Cardiac mitochondria in heart failure: normal cardiolipin profile and increased threonine phosphorylation of complex IV. Biochim. Biophys. Acta 1807, 1373–1382. doi: 10.1016/j.bbabio.2011.02.003
Rosca, M. G., Vazquez, E. J., Kerner, J., Parland, W., Chandler, M. P., Stanley, W., et al. (2008). Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc. Res. 80, 30–39. doi: 10.1093/cvr/cvn184
Rosenberg, P. (2004). Mitochondrial dysfunction and heart disease. Mitochondrion 4, 621–628. doi: 10.1016/j.mito.2004.07.016
Sabbah, H. N., Sharov, V., Riddle, J. M., Kono, T., Lesch, M., and Goldstein, S. (1992). Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J. Mol. Cell. Cardiol. 24, 1333–1347.
Santel, A. (2006). Get the balance right: mitofusins roles in health and disease. Biochim. Biophys. Acta 1763, 490–499. doi: 10.1016/j.bbamcr.2006.02.004
Santulli, G., and Iaccarino, G. (2016). Adrenergic signaling in heart failure and cardiovascular aging. Maturitas 93, 65–72. doi: 10.1016/j.maturitas.2016.03.022
Sato, P. Y., Chuprun, J. K., Grisanti, L. A., Woodall, M. C., Brown, B. R., Roy, R., et al. (2018). Restricting mitochondrial GRK2 post-ischemia confers cardioprotection by reducing myocyte death and maintaining glucose oxidation. Sci. Signal. 11:eaau0144. doi: 10.1126/scisignal.aau0144
Sato, P. Y., Chuprun, J. K., Ibetti, J., Cannavo, A., Drosatos, K., Elrod, J. W., et al. (2015). GRK2 compromises cardiomyocyte mitochondrial function by diminishing fatty acid-mediated oxygen consumption and increasing superoxide levels. J. Mol. Cell. Cardiol. 89(Pt B), 360–364. doi: 10.1016/j.yjmcc.2015.10.002
Schaper, J., Meiser, E., and Stammler, G. (1985). Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. Circ. Res. 56, 377–391.
Shirihai, O. S., Song, M., and Dorn, G. W. II (2015). How mitochondrial dynamism orchestrates mitophagy. Circ. Res. 116, 1835–1849. doi: 10.1161/CIRCRESAHA.116.306374
Soboll, S., Brdiczka, D., Jahnke, D., Schmidt, A., Schlattner, U., Wendt, S., et al. (1999). Octamer-dimer transitions of mitochondrial creatine kinase in heart disease. J. Mol. Cell. Cardiol. 31, 857–866. doi: 10.1006/jmcc.1998.0925
Sorriento, D., Ciccarelli, M., Cipolletta, E., Trimarco, B., and Iaccarino, G. (2016). “Freeze, Don’t Move”: how to arrest a suspect in heart failure - a review on available GRK2 inhibitors. Front. Cardiovasc. Med. 3:48. doi: 10.3389/fcvm.2016.00048
Sorriento, D., Ciccarelli, M., Santulli, G., Illario, M., Trimarco, B., and Iaccarino, G. (2014). Trafficking GRK2: cellular and metabolic consequences of GRK2 subcellular localization. Transl. Med. UniSa 10, 3–7.
Sorriento, D., Fusco, A., Ciccarelli, M., Rungi, A., Anastasio, A., Carillo, A., et al. (2013). Mitochondrial G protein coupled receptor kinase 2 regulates proinflammatory responses in macrophages. FEBS Lett. 587, 3487–3494. doi: 10.1016/j.febslet.2013.09.002
Sorriento, D., Gambardella, J., Fiordelisi, A., Trimarco, B., Ciccarelli, M., Iaccarino, G., et al. (2017). Mechanistic role of kinases in the regulation of mitochondrial fitness. Adv. Exp. Med. Biol. 982, 521–528. doi: 10.1007/978-3-319-55330-6_26
Sorriento, D., Santulli, G., Franco, A., Cipolletta, E., Napolitano, L., Gambardella, J., et al. (2015). Integrating GRK2 and NFkappaB in the pathophysiology of cardiac hypertrophy. J. Cardiovasc. Transl. Res. 8, 493–502. doi: 10.1007/s12265-015-9646-0
Starling, R. C., Hammer, D. F., and Altschuld, R. A. (1998). Human myocardial ATP content and in vivo contractile function. Mol. Cell. Biochem. 180, 171–177.
Tandler, B., Dunlap, M., Hoppel, C. L., and Hassan, M. (2002). Giant mitochondria in a cardiomyopathic heart. Ultrastruct. Pathol. 26, 177–183. doi: 10.1080/01913120290076847
Theccanat, T., Philip, J. L., Razzaque, A. M., Ludmer, N., Li, J., Xu, X., et al. (2016). Regulation of cellular oxidative stress and apoptosis by G protein-coupled receptor kinase-2; the role of NADPH oxidase 4. Cell. Signal. 28, 190–203. doi: 10.1016/j.cellsig.2015.11.013
Tsutsui, H., Kinugawa, S., and Matsushima, S. (2011). Oxidative stress and heart failure. Am. J. Physiol. Heart Circ. Physiol. 301, H2181–H2190. doi: 10.1152/ajpheart.00554.2011
Usui, I., Imamura, T., Satoh, H., Huang, J., Babendure, J. L., Hupfeld, C. J., et al. (2004). GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation. EMBO J. 23, 2821–2829. doi: 10.1038/sj.emboj.7600297
Viola, H. M., and Hool, L. C. (2010). Cross-talk between L-type Ca2+ channels and mitochondria. Clin. Exp. Pharmacol. Physiol. 37, 229–235. doi: 10.1111/j.1440-1681.2009.05277.x
Wang, P., Wu, Y., Ge, X., Ma, L., and Pei, G. (2003). Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J. Biol. Chem. 278, 11648–11653. doi: 10.1074/jbc.M208109200
Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., et al. (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730. doi: 10.1126/science.1059108
Whelan, R. S., Konstantinidis, K., Wei, A. C., Chen, Y., Reyna, D. E., Jha, S., et al. (2012). Bax regulates primary necrosis through mitochondrial dynamics. Proc. Natl. Acad. Sci. U.S.A. 109, 6566–6571. doi: 10.1073/pnas.1201608109
Witherow, D. S., Garrison, T. R., Miller, W. E., and Lefkowitz, R. J. (2004). beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc. Natl. Acad. Sci. U.S.A. 101, 8603–8607. doi: 10.1073/pnas.0402851101
Woodall, M. C., Ciccarelli, M., Woodall, B. P., and Koch, W. J. (2014). G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism. Circ. Res. 114, 1661–1670. doi: 10.1161/CIRCRESAHA.114.300513
Xiao, K., McClatchy, D. B., Shukla, A. K., Zhao, Y., Chen, M., Shenoy, S. K., et al. (2007). Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc. Natl. Acad. Sci. U.S.A. 104, 12011–12016. doi: 10.1073/pnas.0704849104
Youle, R. J., and Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47–59. doi: 10.1038/nrm2308
Zhang, J., Xiao, H., Shen, J., Wang, N., and Zhang, Y. (2017). Different roles of beta-arrestin and the PKA pathway in mitochondrial ROS production induced by acute beta-adrenergic receptor stimulation in neonatal mouse cardiomyocytes. Biochem. Biophys. Res. Commun. 489, 393–398. doi: 10.1016/j.bbrc.2017.05.140
Keywords: G protein-coupled receptor kinase 2, β-arrestins, mitochondria, heart failure, cardiac damage
Citation: Sorriento D, Gambardella J, Fiordelisi A, Iaccarino G and Illario M (2019) GRKs and β-Arrestins: “Gatekeepers” of Mitochondrial Function in the Failing Heart. Front. Pharmacol. 10:64. doi: 10.3389/fphar.2019.00064
Received: 26 October 2018; Accepted: 18 January 2019;
Published: 12 February 2019.
Edited by:
Yuichi Hattori, University of Toyama, JapanReviewed by:
Hitoshi Kurose, Kyushu University, JapanScott M. MacDonnell, Regeneron Pharmaceuticals, Inc., United States
Copyright © 2019 Sorriento, Gambardella, Fiordelisi, Iaccarino and Illario. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daniela Sorriento, ZGFuaWVsYS5zb3JyaWVudG9AdW5pbmEuaXQ= Guido Iaccarino, Z3VpYWNjYXJAdW5pbmEuaXQ=